AbbVie, IMF Team Up to Study Gene Mutation in Myeloma Outcomes
AbbVie and the International Myeloma Foundation are collaborating to study the role of a genetic mutation — the t(11;14) translocation — in multiple myeloma treatments…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
SELLAS Vaccine More Than Doubles Time to Myeloma Progression, Phase 2 Trial Shows
SELLAS Life Sciences’  Galinpepimut-S vaccine more than doubles the time it takes for high-risk multiple myeloma patients’ cancer to worsen, a Phase 2 clinical trial shows.
Medicinal Cannabis Safe and Effective for Pain, Chemo Side Effects, Journal Says
The supervised use of medicinal cannabis is safe and effective at relieving pain and reducing chemotherapy-induced nausea and vomiting in cancer patients, an increasing body of…
Myeloma Patients Refractory to Revlimid May Benefit from Ninlaro, Pomalyst, Dexamethasone Combo
Multiple myeloma patients who failed prior Revlimid (lenalidomide) treatment may benefit from a triple oral combo treatment with Ninlaro (ixazomib), Pomalyst (pomalidomide) and dexamethasone, the results…
Trial to Explore Benefits of Exercise Before Autologous Stem Cell Transplant in Myeloma Patients
A new clinical trial will determine if an exercise program before an autologous stem cell transplant can improve treatment-related side effects in multiple myeloma patients. The…
Seattle Genetics Starts Phase 1 Trial Testing SGN-CD48A in Relapsed or Refractory Myeloma
Seattle Genetics‘ investigational therapy SGN-CD48A, being evaluated in a Phase 1 clinical trial for relapsed or refractory multiple myeloma, was successfully delivered…
